| 1 |
30707764 | Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. | 2019 Jun 1 |
1 |
| 2 |
24236538 | AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. | 2014 Feb |
1 |
| 3 |
22109882 | The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. | 2012 Feb |
2 |
| 4 |
22171982 | Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. | 2012 Apr |
1 |
| 5 |
23012246 | RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. | 2012 Dec |
1 |